| Gallstone disease is associated with more severe liver damage in patients with non-alcoholic fatty liver disease AL Fracanzani, L Valenti, M Russello, L Miele, C Bertelli, A Bellia, ... PloS one 7 (7), e41183, 2012 | 115 | 2012 |
| Multiclass HCV resistance to direct‐acting antiviral failure in real‐life patients advocates for tailored second‐line therapies VC Di Maio, V Cento, I Lenci, M Aragri, P Rossi, S Barbaliscia, M Melis, ... Liver international 37 (4), 514-528, 2017 | 99 | 2017 |
| Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis V Sapena, M Enea, F Torres, C Celsa, J Rios, GEM Rizzo, P Nahon, ... Gut 71 (3), 593-604, 2022 | 78 | 2022 |
| High mortality in COVID‐19 patients with mild respiratory disease C Masetti, E Generali, F Colapietro, A Voza, M Cecconi, A Messina, ... European journal of clinical investigation 50 (9), e13314, 2020 | 60 | 2020 |
| Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis L Rinaldi, F Nascimbeni, M Giordano, C Masetti, B Guerrera, A Amelia, ... World Journal of Gastroenterology 23 (8), 1458, 2017 | 58 | 2017 |
| Prevalence of single and multiple natural NS3, NS5A and NS5B resistance-associated substitutions in hepatitis C virus genotypes 1–4 in Italy A Bertoli, MC Sorbo, M Aragri, I Lenci, E Teti, E Polilli, VC Di Maio, ... Scientific reports 8 (1), 8988, 2018 | 49 | 2018 |
| Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? VC Di Maio, V Cento, M Aragri, S Paolucci, T Pollicino, N Coppola, ... Journal of hepatology 68 (3), 597-600, 2018 | 39 | 2018 |
| Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma E Lanza, C Masetti, G Messana, R Muglia, N Pugliese, R Ceriani, ... PLoS One 15 (6), e0232371, 2020 | 33 | 2020 |
| HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study AM Ippolito, M Milella, V Messina, F Conti, R Cozzolongo, F Morisco, ... Digestive and liver disease 49 (9), 1022-1028, 2017 | 20 | 2017 |
| A different perspective on sofosbuvir‐ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The ital‐c network study M Barone, A Iannone, E Shahini, AM Ippolito, G Brancaccio, F Morisco, ... Journal of Viral Hepatitis 25 (1), 56-62, 2018 | 18 | 2018 |
| Lack of reduction in serum alpha‐fetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with … C Masetti, R Lionetti, M Lupo, M Siciliano, V Giannelli, FR Ponziani, E Teti, ... Journal of viral hepatitis 25 (12), 1493-1500, 2018 | 17 | 2018 |
| Prevalence of resistance-associated substitutions and retreatment of patients failing a glecaprevir/pibrentasvir regimen A de Salazar, J Dietz, VC di Maio, J Vermehren, S Paolucci, B Müllhaupt, ... Journal of Antimicrobial Chemotherapy 75 (11), 3349-3358, 2020 | 15 | 2020 |
| Resistance analysis and treatment outcomes in hepatitis C virus genotype 3‐infected patients within the Italian network VIRONET‐C VC Di Maio, S Barbaliscia, E Teti, G Fiorentino, M Milana, S Paolucci, ... Liver International 41 (8), 1802-1814, 2021 | 14 | 2021 |
| Impact of chronic exposure to 5-alpha reductase inhibitors on the risk of hospitalization for COVID-19: a case-control study in male population from two COVID-19 regional … M Lazzeri, S Duga, E Azzolini, V Fasulo, N Buffi, A Saita, G Lughezzani, ... Minerva Urology and Nephrology 74 (1), 77-84, 2021 | 13 | 2021 |
| Bulevirtide for treatment of patients with HDV infection and compensated cirrhosis: A (huge?) step in the right direction. C Masetti, A Aghemo Liver International 41 (7), 2021 | 8 | 2021 |
| Ursodeoxycholic acid does not improve COVID-19 outcome in hospitalized patients F Colapietro, G Angelotti, C Masetti, D Shiffer, N Pugliese, S De Nicola, ... Viruses 15 (8), 1738, 2023 | 6 | 2023 |
| Aghemo A Humanitas HCC Multidisciplinary Group. Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular … E Lanza, C Masetti, G Messana, R Muglia, N Pugliese, R Ceriani, ... PLoS One 15, e0232371, 2020 | 6 | 2020 |
| Optimization of direct anti-viral agent treatment schedule: Focus on HCV genotype 3 F Morisco, R Granata, S Camera, A Ippolito, M Milella, F Conti, C Masetti, ... United European Gastroenterology Journal 6 (2), 225-237, 2018 | 6 | 2018 |
| HCV Italian Resistance Network Study Group Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies VC Di Maio, V Cento, I Lenci, M Aragri, P Rossi, S Barbaliscia, M Melis, ... Liver Int. Off. J. Int. Assoc. Study Liver 37, 514-528, 2017 | 6 | 2017 |
| Postsustained virological response management in hepatitis C patients C Masetti, A Lleo, M Colombo, M Colombo, A Aghemo Seminars in Liver Disease 40 (03), 233-239, 2020 | 5 | 2020 |
